Hospital Infanta Leonor-ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

  3. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

    Viruses, Vol. 15, Núm. 4

2022

  1. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

2021

  1. Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation

    BMC Cardiovascular Disorders, Vol. 21, Núm. 1

  2. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

    The Lancet Infectious Diseases, Vol. 21, Núm. 6, pp. 783-792

  3. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Clinical Microbiology and Infection, Vol. 27, Núm. 2, pp. 244-252

2020

  1. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain

    Clinical Microbiology and Infection, Vol. 26, Núm. 11, pp. 1525-1536

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118

  2. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  3. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

  4. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2016

  1. Characteristics of HIV infected individuals traveling abroad. Results from the +REDIVI Collaborative Network

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 2, pp. 108-113

  2. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

  4. Systemic activity and mortality in primary Sjögren syndrome: Predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 2, pp. 348-355

  5. Travelers' diarrhea in children at risk: An observational study from a Spanish database

    Pediatric Infectious Disease Journal, Vol. 35, Núm. 4, pp. 392-395

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394